Needham & Company Starts AMAG Pharmaceuticals (AMAG) at Buy

Needham & Company initiates coverage on AMAG Pharmaceuticals (NASDAQ: AMAG) with a Buy rating and a price target of $40.00.

Analyst Serge Belanger commented, "We are initiating coverage of AMAG Pharmaceuticals (AMAG), a growth-oriented specialty biopharma, with a Buy and $40PT. A one-product company until 2014, AMAG has transformed itself via acquisitions into a profitable cash-flow generating co. with three growth products across two therapeutic platforms (maternal health and hematology/oncology). AMAG's three products (Makena, Feraheme and CBR) are primed for continued expansion, fueled by favorable market dynamics and strong commercial execution capabilities. We expect the generic risk around Makena will be mitigated by the ongoing life-cycle management program. Beyond organic growth, AMAG's strong cash flows and debt capacity should drive business development activity that can generate additional revenue growth and further diversify the product offerings."

For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.

Shares of AMAG Pharmaceuticals closed at $26.35 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen
• Tyler Tech (TYL) PT Raised to $500 at Oppenheimer